European Association For The Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A.

United statesJean pierre sommadossiJonae barnesQi huangAlina jucovAtea pharmaceuticals incGlobenewswire incCorporate communicationsAtea pharmaceuticalsEuropean association for the studyWhile the companyInclude new antiviral efficacy resultsLead in cohortOngoing phaseAlso highlightHigh prevalence

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver.

United statesMarie ofarrellMaria yonkoskiRohit loombaSagimet biosciencesGlobenewswire incResearch centerEuropean association for the studySagimet biosciences incDivision of gastroenterologyUniversity of california san diegoExchange commissionLiver diseasesMarieo farrellSenior vice presidentInhibitor alone

Data from 89bio s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress

– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints – – New data showed pegozafermin resulted in sig.

San franciscoUnited statesUniversity of california san diegoRohit loombaArunj sanyalBryan martinsSheryl seapyHank mansbachLifesci advisorsVirginia commonwealth university vcuhealthEuropean association for the studyGlobenewswire incDivision of gastroenterologyEngland journalControlled trialCalifornia san diego school

Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC including ALP,. | June 7, 2023

United statesAntonio civitareseKaren prebleFrederik nevensAlexandre louvetLynda szczechNareg sagherianM michelle berreyCheng zouVaclav hejdaResearch developmentGlobenewswire incCompany on twitterIntercept pharmaceuticals incEuropean association for the studyGlobal corporate communications

Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)

Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNareg sagherianKaren prebleM michelle berreyDrug administrationGlobal corporate communicationsIntercept pharmaceuticals incEuropean association for the studyOffice of orphan drug productsResearch developmentCompany on twitterChief medical officerEuropean associationOrphan drug productsBezafibrate fixed dose combinationinterceptPrimary biliary cholangitisprimary